Prescient Therapeutics Investor Briefing – 19 October

October 19, 2021

Prescient Therapeutics Investor Briefing – 19 October

Prescient Therapeutics (ASX: PTX) Webcast Replay

19th October, 2021

Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke and Director of Scientific Affairs, Rebecca Lim, present a special ‘OmniCAR Explainer’ session. They provide an overview into the amazing field of CAR-T and step through the new preclinical data, which demonstrates key OmniCAR features in next gen CAR-Ts.

Recorded on 19 October 2021 at 11am (AEDT).

Join the next Prescient Therapeutics webcast 

Speak to the Reach Markets team


Steven Yatomi-Clarke

Chief Executive Officer - Prescient Therapeutics (ASX: PTX)

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.

Dr Rebecca Lim

Director of Scientific Affairs - Prescient Therapeutics (ASX: PTX)

Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.

Speak to the Reach Markets team

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.